The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2024 | DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti, MD, Johns Hopkins University School of Medicine, Baltimore, MD, gives an overview of a new Phase I/II trial (NCT06027086) using DRP-104 with durvalumab to treat fibrolamellar hepatocellular carcinoma (FLC). Using the glutamine antagonist to encourage metabolic reprogramming reduces immunity to immune checkpoint inhibitor (ICI) treatment in patients with FLC. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
